3M Partnership With Cummins Expected to Increase Production of Filters for Powered Air Purifying Respirators

April 14, 2020

3M announced they have established a partnership with Cummins to increase the production of high-efficiency particulate filters for use in 3M’s powered air-purifying respirators, or PAPRs.

3M notes the partnership has the potential to more than double the current production of filters for 3M’s PAPRs. The additional filters are needed as the company has ramped up the production of PAPRs to meet a surge in demand for personal protective equipment due to the COVID-19 outbreak.

The company’s powered air-purifying respirators (PAPRs) are an important piece of personal protective equipment for front-line healthcare workers. PAPRs use a battery-powered blower that sends filtered air into a hood or head top that covers the head or face, and can provide increased levels of respiratory protection, especially for critical healthcare situations such as aerosol-generating procedures. PAPRs may also be more comfortable to wear for those who need respiratory protection for long periods of time.

Guided by a 3M design, employees in Cummins’ facility in Neillsville, Wisconsin, will use existing equipment typically used for producing diesel engine filters to make the PAPR filters. After assembly and testing, the filters will be sent to 3M’s plant in Valley, Nebraska, where the company’s PAPRs are manufactured. Production of the filters at Cummins Neillsville location is expected to begin by the end of April.

“3M continues to work around the clock to get personal protective equipment, including PAPRs, to the heroic healthcare workers and first responders on the frontlines of the COVID-19 fight,” said Mike Roman, 3M chairman of the board and chief executive officer. “Our partnership with Cummins will help us produce more of this critical equipment in the coming months.”

“Cummins has been striving to find out ways to help during the COVID-19 crisis,” said Tom Linebarger, Chairman and Chief Executive Officer of Cummins. “Working with 3M, we discovered that our technologies and manufacturing expertise could be relevant as we partner in new ways to help protect healthcare professionals.”

Since the COVID-19 outbreak began, 3M has increased production of critical safety and healthcare products at its manufacturing facilities in the U.S. and around the world. Beginning in January, 3M ramped up production of N95 and other respirators and doubled its global output to 1.1 billion per year – including 35 million a month in the United States. 3M has already put into motion additional investments and actions that will enable it to double its capacity again to 2 billion globally within 12 months, with additional capacity to begin coming online in the next 60 to 90 days. In the United States, 3M expects to produce N95 respirators at a rate of 50 million per month in June, a 40 percent increase from current levels.

3M is also working with the Trump administration on a plan to import 166.5 million 3M respirators from its overseas manufacturing facilities, starting this month.

In March, 3M announced a separate partnership with Ford to increase the production of PAPRs. 3M continues to explore opportunities to further expand its capacity and get healthcare supplies to where they’re needed most as quickly as possible.

Source3M
Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy